David Gershenson
Overview
Explore the profile of David Gershenson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
709
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ray-Coquard I, Ledermann J, DeFazio A, Okamoto A, Gershenson D
Int J Gynecol Cancer
. 2025 Mar;
35(3):101669.
PMID: 40022843
More than half of all gynecological cancers are classified as rare (annual incidence <6 per 100,000), and present significant challenges in diagnosis, management, and research. Rare cancers collectively comprise more...
2.
Brodsky A, Flores Legarreta A, Fellman B, Glassman D, How J, Vuttaradhi V, et al.
Int J Gynecol Cancer
. 2024 Oct;
PMID: 39395821
Objectives: To evaluate survival outcomes among patients with adult-type granulosa cell tumors who have telomerase reverse transcriptase () promoter mutations. Methods: This is a retrospective cohort study using the MD...
3.
Grisham R, Monk B, Van Nieuwenhuysen E, Moore K, Fabbro M, OMalley D, et al.
Int J Gynecol Cancer
. 2024 Oct;
PMID: 39375168
Background: There are no approved treatments specifically for low grade serous ovarian cancer; current standard of care treatment options are limited in efficacy and tolerability. The combination of avutometinib with...
4.
Nasioudis D, Wang X, Dhillon G, Latif N, Ko E, Giuntoli 2nd R, et al.
Int J Gynecol Cancer
. 2023 Oct;
33(12):1906-1912.
PMID: 37879909
Objective: To investigate the use and outcomes of adjuvant chemotherapy for patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery. Methods: Patients diagnosed between 2010 and 2015 with...
5.
Cobb L, Gershenson D
Int J Gynecol Cancer
. 2023 Mar;
33(3):377-384.
PMID: 36878564
Low-grade serous ovarian cancer is a rare subtype of epithelial ovarian cancer clinically characterized by younger age at diagnosis, relative chemoresistance, and prolonged survival compared with its high-grade serous counterpart....
6.
Westin S, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, et al.
Gynecol Oncol
. 2022 Nov;
168:76-82.
PMID: 36423446
Objective: Selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound which blocks Exportin-1 (XPO1). Our objective was to determine maximum tolerated dose (MTD) and recommended phase II...
7.
Hillman R, Gershenson D
Int J Gynecol Cancer
. 2021 Jan;
31(2):169-170.
PMID: 33436449
No abstract available.
8.
Phoolcharoen N, Woodard T, James D, Patel D, Roder S, Holman D, et al.
Gynecol Oncol Rep
. 2020 May;
32:100576.
PMID: 32405521
•Small cell carcinoma of the ovary hypercalcemic type (SCCOHT) is a rare neoplasm that mostly affects young women.•The chances of future fertility in women are limited due to the aggressive...
9.
Hackshaw A, Gershenson D, Ledermann J
N Engl J Med
. 2019 Jul;
381(1):e3.
PMID: 31269388
No abstract available.
10.
Siemon J, Gershenson D, Slomovitz B, Schlumbrecht M
Gan To Kagaku Ryoho
. 2018 Feb;
45(2):247-255.
PMID: 29483415
No abstract available.